174 related articles for article (PubMed ID: 17876335)
1. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
12. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Feliu J; Salud A; Escudero P; Lopez-Gómez L; Bolaños M; Galán A; Vicent JM; Yubero A; Losa F; De Castro J; de Mon MA; Casado E; González-Barón M
Br J Cancer; 2006 Apr; 94(7):969-75. PubMed ID: 16552438
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
14. Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Dong N; Jiang W; Li H; Liu Z; Xu X; Wang M
Am J Clin Oncol; 2009 Dec; 32(6):559-63. PubMed ID: 19581793
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine for treatment of advanced hepatocellular carcinoma.
von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Park YH; Lee JL; Ryoo BY; Ryu MH; Yang SH; Kim BS; Shin DB; Chang HM; Kim TW; Yuh YJ; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):623-9. PubMed ID: 17522863
[TBL] [Abstract][Full Text] [Related]
17. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.
Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J
J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M
Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
